The results of the national selection of insulin are released!

The results of the national selection of insulin were officially announced.
All the supplied varieties involved 91 brands.
All 11 companies were selected except for the protamine insulin of Jiangsu Wanbang, with an average drop of 48.
75% and a highest drop of 73.
76%
.
The 15 varieties dropped by more than 50%, and the total purchase amount involved was about 7.
28 billion yuan, which was 55% less than the reported volume
.
On November 30, the National Organization for Pharmaceutical Joint Procurement Office officially announced the results of the sixth batch of national procurement (insulin special) selection, and announced the list of products to be supplied after the selection.
The 6 procurement groups involved a total of 91 brand selections
.
In this centralized insulin procurement, a total of 11 manufacturers participated in the declaration.
Except for Jiangsu Wanbang’s protamine insulin, which was not selected (which will be classified as group D, and its reported amount will be allocated), the products of the other manufacturers were selected
.
The average drop of selected varieties was 48.
75%, and the highest drop was 73.
76%
.
The purchase amount corresponding to the basic purchase amount of all varieties of this centralized procurement is 5.
880 billion yuan, and the purchase amount allocated by the two groups C and D is 1.
401 billion yuan.
The basic purchase amount plus the amount to be allocated, the corresponding purchase amount is approximately 7.
28 billion yuan, compared with the 16.
1 billion yuan calculated based on the reported volume and the highest effective declared price, the volume part has shrunk as much as 8.
82 billion yuan, with a shrinkage rate of 55%
.
The evaporation of the basic procurement volume of each group is worthy of attention.
According to the incomplete statistics of the Medical Cloud Studio, the total procurement amount of this centralized procurement is about 7.
28 billion yuan, of which the procurement amount corresponding to the basic procurement volume of all varieties is 5.
88 billion yuan.
C The corresponding amount of purchases allocated by the two groups D is 1.
401 billion yuan
.
However, one thing worth noting is that according to the rules of selection, only entering the A1 group can get all the basic purchases, other groups can only get part of the basic purchases, and the selected products in category C are only allocated 30%, and category D is allocated 80%.
%To group A and B, how to deal with the remaining basic purchase volume? How will this part of the market be distributed in the future? I believe this is what major pharmaceutical companies need to pay attention to
.
Remarks: 1) Jiangsu Wanbang’s protamine human insulin was not selected, and the allocated purchase amount is temporarily calculated based on the quoted price of 33.
75 yuan.
Others are calculated based on the proposed price.
2) The basic purchase volume of some selected varieties has not been announced and cannot be included in the calculation scope of 15 varieties A drop of over 50% According to the statistics of the medical cloud studio, the average drop of the selected varieties of insulin in this centralized procurement relative to the limit price was 48.
75%, and the highest drop was 73.
76%
.
Among them, the average decline of imported varieties was 45.
24%, and the average decline of domestic varieties was 50.
50%
.
There are 15 varieties with a decrease of more than 50%
.
Among them, the average bid price of second-generation insulin was 27.
25 yuan (3ml: 300/piece), which was an average decrease of 45.
51% compared to the limit price, the largest decrease of Ganli Pharmaceutical's protamine and human insulin mixed injection (30R), the selected price was 17.
89, a decrease Up to 64.
22%
.
The average price of the three-generation meal-time insulin and its premixed selection was 32.
14 yuan (3ml: 300/piece), an average decrease of 55.
36% compared to the limit price.
The largest decrease was Eli Lilly’s protamine zinc recombinant insulin lispro mixed injection ( 25R), the winning price was 18.
89%, a decrease of 73.
76%
.
The average selected price of the three generations of basal insulin was 70.
44 yuan (3ml: 300/piece), which was an average drop of 46.
63% compared to the limit price.
The biggest drop was the insulin glargine injection of Ganli Pharmaceutical, with the selected price of 48.
71 yuan, a drop of 63.
10%.

.
Novo Nordisk selected the largest number of varieties, reaching 7; domestic Ganli Pharmaceutical and Zhuhai Federation each had 6 varieties.
From the number of selected varieties of each company, Novo Nordisk, a foreign company, had the largest number of selected varieties, domestic pharmaceutical companies, Ganli Pharmaceutical and Zhuhai There are 6 in each of the federations, ranking second
.
Eli Lilly and Tonghua Dongbao each have 5, ranking third
.
Five pharmaceutical companies, including Hisun and Ganli Pharmaceutical, dropped by more than 50% on average.
Some industry insiders predicted that this time of concentrated insulin procurement, domestic manufacturers are likely to seize the market share of the three major multinational pharmaceutical companies by virtue of their price advantages.

.
Judging from the average decline in the selected varieties of various companies, domestic companies are indeed very impressive
.
Zhejiang Hisun, Ganli Pharmaceutical, Hefei Yifan and Hefei Tianmai all experienced an average decline of more than 50%
.
This time, Eli Lilly’s average drop also reached 52.
21%
.
Among them, Eli Lilly’s protamine zinc recombinant insulin lispro mixed injection (25R) was quoted at only 18.
89 yuan, a decrease of 74%, and it was the first to enter A1 in the same group, which successfully divided part of Novo Nordisk’s market.

.
However, Novo Nordisk, Jiangsu Wanbang, and Dongyang Sunshine are basically short-listed finalists, and the declines are all within 41%
.
Although they are selected successfully, if they are assigned to Group C, only 50% of the basic purchases will be obtained, and a large part of the basic purchases will still be allocated
.
I believe that how to grasp the margin market from now on is worth planning for all companies
.